317 related articles for article (PubMed ID: 9531535)
1. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
Reuther JY; Reuther GW; Cortez D; Pendergast AM; Baldwin AS
Genes Dev; 1998 Apr; 12(7):968-81. PubMed ID: 9531535
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Kirchner D; Duyster J; Ottmann O; Schmid RM; Bergmann L; Munzert G
Exp Hematol; 2003 Jun; 31(6):504-11. PubMed ID: 12829026
[TBL] [Abstract][Full Text] [Related]
3. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D; Kadlec L; Pendergast AM
Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
[TBL] [Abstract][Full Text] [Related]
4. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
Hsieh MY; Van Etten RA
Blood; 2014 Apr; 123(15):2401-11. PubMed ID: 24464015
[TBL] [Abstract][Full Text] [Related]
5. The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.
Carrà G; Torti D; Crivellaro S; Panuzzo C; Taulli R; Cilloni D; Guerrasio A; Saglio G; Morotti A
Oncotarget; 2016 Oct; 7(40):66287-66298. PubMed ID: 27563822
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
Lu Y; Jamieson L; Brasier AR; Fields AP
Oncogene; 2001 Aug; 20(35):4777-92. PubMed ID: 11521190
[TBL] [Abstract][Full Text] [Related]
7. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.
Nawata R; Yujiri T; Nakamura Y; Ariyoshi K; Takahashi T; Sato Y; Oka Y; Tanizawa Y
Oncogene; 2003 Oct; 22(49):7774-80. PubMed ID: 14586403
[TBL] [Abstract][Full Text] [Related]
8. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
9. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Mukhopadhyay A; Shishodia S; Suttles J; Brittingham K; Lamothe B; Nimmanapalli R; Bhalla KN; Aggarwal BB
J Biol Chem; 2002 Aug; 277(34):30622-8. PubMed ID: 12060665
[TBL] [Abstract][Full Text] [Related]
10. Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
Vázquez-Franco JE; Reyes-Maldonado E; Vela-Ojeda J; Domínguez-López ML; Lezama RA
Leuk Res; 2012 Jul; 36(7):862-7. PubMed ID: 22591684
[TBL] [Abstract][Full Text] [Related]
11. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB).
Hamdane M; David-Cordonnier MH; D'Halluin JC
Oncogene; 1997 Nov; 15(19):2267-75. PubMed ID: 9393872
[TBL] [Abstract][Full Text] [Related]
12. Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Munzert G; Kirchner D; Ottmann O; Bergmann L; Schmid RM
Leuk Lymphoma; 2004 Jun; 45(6):1181-4. PubMed ID: 15359998
[TBL] [Abstract][Full Text] [Related]
13. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
Sattler M; Salgia R
Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
15. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
[TBL] [Abstract][Full Text] [Related]
17. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
18. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
19. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
20. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
